AYTU BIOPHARMA, INC. - 10-Q Summary (Q1 Fiscal 2026)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025 (Q1 Fiscal 2026). Aytu BioPharma, Inc. is a pharmaceutical company focused on central nervous system (CNS) diseases. Following the divestiture of its Consumer Health business in July 2024, the Company now operates as a single segment focused on its ADHD Portfolio, Pediatric Portfolio, and the upcoming commercialization of EXXUA (gepirone), a novel antidepressant. The Company indefinitely suspended active clinical development programs to prioritize commercial operations and achieve positive operating cash flows.
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Revenue | $13.9 million | $16.6 million |
| Gross Profit | $9.2 million (66% margin) | $12.0 million (72% margin) |
| Net Income | $2.0 million | $1.5 million |
| Operating Cash Flow | ($0.6 million) used | ($1.2 million) used |
| Cash and Equivalents | $32.6 million | $20.1 million |
| Total Debt (Current + Non-Current) | $27.2 million | $N/A (Prior period structure differed) |
| Derivative Warrant Liabilities | $20.4 million | $26.3 million |
Note: Net income includes a non-cash gain of $3.8 million from the revaluation of derivative warrant liabilities. Operating loss from continuing operations was $1.5 million.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 16% to $13.9 million. This decline is primarily attributed to the absence of a $3.3 million one-time revenue increase recorded in Q1 2025 related to a vendor negotiation settlement regarding variable consideration.
- Expense Reduction: Total operating expenses decreased by $2.2 million (17%). Notable reductions include:
- R&D: Dropped to $0 from $0.4 million due to the suspension of clinical development programs.
- Restructuring: Dropped to $0 from $0.8 million as operational realignment activities were completed.
- Amortization: Decreased by $0.5 million due to prior impairments of intangible assets.
- Debt and Liquidity: The Company increased borrowings under its revolving credit facility by $5.8 million during the quarter. Cash balances increased by $1.7 million, driven by financing activities and improved operating cash flow efficiency.
- Warrant Liability Gain: A $3.8 million gain was recognized due to the decrease in the fair value of derivative warrant liabilities, driven by a decline in the Company's stock price.
Outlook, Risks, and Management Commentary
- EXXUA Launch: Management anticipates launching EXXUA in the second quarter of fiscal 2026. The Company entered an exclusive commercialization agreement with Fabre-Kramer Holdings, Inc., involving an upfront payment of $3.0 million and potential future milestone payments exceeding $100 million based on sales thresholds.
- Strategic Focus: The Company is winding down unprofitable operations and focusing on commercializing ADHD products and EXXUA. International collaborations with Medomie (Israel/Palestine) and Lupin (Canada) for ADHD products are ongoing, with regulatory approvals expected over the next 24 months.
- Legal Risks:
- Granules Litigation: A patent infringement lawsuit regarding Adzenys XR-ODT is ongoing. The trial date has been rescheduled to January 11, 2027. A generic entry could materially impact the ADHD portfolio.
- Generic Competition: Agreements with Teva and Actavis allow for generic entry of certain ADHD products starting in 2025 and 2026, though launches have not yet occurred.
- Capital Resources: The Company maintains a $100 million shelf registration (Form S-3) and recently raised $16.6 million in gross proceeds in June 2025 to fund working capital and the EXXUA launch.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue excluding the $3.3 million one-time adjustment from the prior year.
- EXXUA Commercialization: Confirm the timeline and budget for the Q2 2026 launch and the terms of the Fabre-Kramer agreement (royalties and milestones).
- Patent Litigation Status: Monitor the Granules Pharmaceuticals lawsuit regarding Adzenys, as a loss could accelerate generic competition.
- Debt Covenants: Review compliance with the Eclipse Agreement covenants, particularly given the reliance on the revolving credit facility.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the derivative warrant liability valuation and its effect on reported net income.